Skip to main content

Table 3 Trial characteristics

From: Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective

Author Quality score Total N Vasopressors atenrollment Etomidate used Steroid type Steroid-days before tapering Tapering days Hydrocortisone equivalent (mg) Age Steroid Age Placebo %males Steroid %males Placebo
Cooperative Study Group [32] 7 194 NA NA Hydrocortisone 1 2-6 1050 NA NA 70.8 64.3
Klastersky and colleagues [41] 7.5 85 NA NA Betamethasone 3 None 7000 NA NA 60.1 46.2
Schumer [31] 6 172 NA NA Methyl-prednisolone Bolus-day1 None 8050 49 51 NA NA
      Dexamethasone Repeat unspecified None      
Sprung and colleagues [43] 8.5 59 Yes (93%) NA Methyl-prednisolone Bolus-day1 None 18884 56.5 48 83.7 62.5
      Dexamethasone Repeat in 74%       
Bone and colleagues [38] 10 382 NA NA Methyl-prednisolone 4 doses in 24 hours None 42000 53 53.7 NA NA
Luce and colleagues [46] 11 75 Yes (44%) NA Methyl-prednisolone 4 doses in 24 hours None 42000 50 53 68.4 83.8
Bollaert and colleagues [37] 13.5 41 Yes NA Hydrocortisone 5 6 2175 58.7 56.8 68.2 63.2
Briegel and colleagues [39] 13.5 40 Yes NA Hydrocortisone 3 3-14 2126 47 51 45 60
Chawla and colleagues [47] NA 44 Yes NA Hydrocortisone 3 4 1350 NA NA NA NA
Yildiz and colleagues [45] 9 40 NA NA Prednisolone 10 None 300 57.8 56.5 65 55
Annane and colleagues [36] 14.5 291 Yes Yes Hydrocortisone 7 None 1400 62 60 64 69.8
Tandan and colleagues [44] NA 28 NA NA NA NA NA NA NA NA NA NA
Oppert and colleagues [42] 12.5 41 Yes Yes Hydrocortisone 2-3 2-5 856 59 47 72.2 82.6
Sprung and colleagues [8] 14.5 499 Yes (98.5%) Yes Hydrocortisone 5 6 1800 63 63 66.1 67.8
  1. NA, not available.